Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

被引:15
作者
Qiu, YH [1 ]
Bhattacharjee, S [1 ]
Kraft, P [1 ]
John, TM [1 ]
Craig, E [1 ]
Haynes-Johnson, D [1 ]
Guan, JH [1 ]
Jiang, WQ [1 ]
Macielag, M [1 ]
Sui, ZH [1 ]
Clancy, J [1 ]
Lundeen, S [1 ]
机构
[1] RW Johnson & Johnson Pharmaceut Res & Dev Inst, Drug Discovery, Reprod Therapeut, Raritan, NJ 08869 USA
关键词
phosphodiesterase; phosphodiesterase type 5 inhibitor; erectile dysfunction; corpus cavernosum;
D O I
10.1016/S0014-2999(03)01868-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have characterized a novel, potent, and selective phosphodiesterase type 5 inhibitor, JNJ-10258859 ((R)-(-)-3-(2,3-dihydrobenzofuran-5-yl)-2-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-1,2,3,4-tetrahydro-pyrrolo[3,4-b]quinolin-9-one). Its inhibitory effects on phosphodiesterase 1-6 were determined using enzymes partially purified from human tissues. The compound inhibited phosphodiesterase type 5 with a K-i of 0.23 nM and displayed excellent selectivity versus phosphodiesterase types 1-4 (greater than or equal to 22,000 fold compared to phosphodiesterase type 5). It had 27-fold selectivity over phosphodiesterase type 6 as well. In a cell-based assay, JNJ-10258859 was more potent than sildenafil in potentiating nitric oxide (NO) induced accumulation of intracellular cGMP. The in vivo effect of JNJ-10258859 was evaluated in an anesthetized dog model via intravenous administration. The compound had similar efficacy to sildenafil in enhancing both the amplitude and duration of intracavernosal pressure increase induced by electrical stimulation to the pelvic nerve. No significant effects on either mean aortic pressure or heart rate were observed during the course of the experiments. This data suggests that JNJ-10258859 could be a useful treatment for erectile dysfunction. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 28 条
[1]  
Boolell M, 1996, Int J Impot Res, V8, P47
[2]   NITRIC-OXIDE - A PHYSIOLOGICAL MEDIATOR OF PENILE ERECTION [J].
BURNETT, AL ;
LOWENSTEIN, CJ ;
BREDT, DS ;
CHANG, TSK ;
SNYDER, SH .
SCIENCE, 1992, 257 (5068) :401-403
[3]  
CARTER AJ, 1998, J UROLOGY, V160, P212
[4]   CHARACTERIZATION OF A NOVEL POTENT AND SPECIFIC INHIBITOR OF TYPE-V PHOSPHODIESTERASE [J].
COSTE, H ;
GRONDIN, P .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (10) :1577-1585
[5]   The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil [J].
de Tejada, IS ;
Angulo, J ;
Cuevas, P ;
Ferndández, A ;
Moncada, I ;
Allona, A ;
Lledó, E ;
Körschen, HG ;
Niewöhner, U ;
Haning, H ;
Pages, E ;
Bischoff, E .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2001, 13 (05) :282-290
[6]  
Eardley I, 1997, Expert Opin Investig Drugs, V6, P1803, DOI 10.1517/13543784.6.12.1803
[7]   IMPOTENCE AND ITS MEDICAL AND PSYCHOSOCIAL CORRELATES - RESULTS OF THE MASSACHUSETTS MALE AGING STUDY [J].
FELDMAN, HA ;
GOLDSTEIN, I ;
HATZICHRISTOU, DG ;
KRANE, RJ ;
MCKINLAY, JB .
JOURNAL OF UROLOGY, 1994, 151 (01) :54-61
[8]  
Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1
[9]  
GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133
[10]  
HAMET P, 1978, J CYCLIC NUCL PROT, V4, P281